2021
DOI: 10.1093/jac/dkab152
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial

Abstract: Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. The majority of patients experience asymptomatic to mild self-limited disease, but some cases progress to respiratory and multi-organ failure. However, so far, no approved antiviral therapy has been available for treatment of COVID-19. Sofosbuvir/velpatasvir (SOF/VEL) is an approved anti-HCV drug that is capable of suppressing other families of positive-sense RNA viruses with cons… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
28
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 19 publications
(32 citation statements)
references
References 25 publications
(25 reference statements)
2
28
0
Order By: Relevance
“…One study was originally included, but was later retracted due to concerns about data integrity, and thus was excluded [ 42 ]. Antiviral treatments compared in the included studies were umifenovir (Arbidol) [ 25 , 29 , 31 , 47 ], baloxavir marboxil [ 30 ], enisamium [ 50 ], favipiravir [ 25 , 30 , 35 , 40 42 , 44 , 45 , 48 , 52 ], lopinavir/ritonavir (LPV/r) [ 24 , 26 , 27 , 29 , 31 , 37 , 38 , 44 , 47 ], remdesivir [ 23 , 34 , 36 , 39 , 51 , 53 ], ribavirin [ 22 ], sofosbuvir/daclatasvir [ 22 , 32 , 33 , 46 , 49 ], sofosbuvir/ledipasvir [ 28 ], sofosbuvir/ravidasvir [ 46 ], and sofosbuvir/velpatasvir [ 43 ]. The study characteristics and baseline patient characteristics are summarized in Table 2 .…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…One study was originally included, but was later retracted due to concerns about data integrity, and thus was excluded [ 42 ]. Antiviral treatments compared in the included studies were umifenovir (Arbidol) [ 25 , 29 , 31 , 47 ], baloxavir marboxil [ 30 ], enisamium [ 50 ], favipiravir [ 25 , 30 , 35 , 40 42 , 44 , 45 , 48 , 52 ], lopinavir/ritonavir (LPV/r) [ 24 , 26 , 27 , 29 , 31 , 37 , 38 , 44 , 47 ], remdesivir [ 23 , 34 , 36 , 39 , 51 , 53 ], ribavirin [ 22 ], sofosbuvir/daclatasvir [ 22 , 32 , 33 , 46 , 49 ], sofosbuvir/ledipasvir [ 28 ], sofosbuvir/ravidasvir [ 46 ], and sofosbuvir/velpatasvir [ 43 ]. The study characteristics and baseline patient characteristics are summarized in Table 2 .…”
Section: Resultsmentioning
confidence: 99%
“…Of the RCTs that used sofosbuvir/daclatasvir, all five reported significantly better results for the treatment group for at least one outcome, although the magnitude of the effect was often small [ 22 , 32 , 33 , 46 , 49 ]. Of the three RCTs that included sofosbuvir combined with drugs other than daclatasvir, none reported significant differences between the treatment and control groups [ 28 , 43 , 46 ].…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…A combination of SOF/velpatasvir was also found ineffective in improving clinical status or reducing mortality rates. 36 So, clinical trials investigating monotherapy versus a combination of antivirals drugs to elucidate this hypothesis are recommended.…”
Section: Discussionmentioning
confidence: 99%